Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04714320 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure
A Phase 2 study of Hypertension, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT04714320 is a Phase 2 study of Hypertension that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 160 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT04714320, a Phase 2 study of Hypertension, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the effect of IONIS-AGT-LRx compared to placebo on seated automated office systolic blood pressure (SBP) from baseline to Study Day 85 in uncontrolled hypertensive participants on ≥ 3 antihypertensive medications and to evaluate the effect of IONIS-AGT-LRx on ambulatory blood pressure, seated automated office SBP, seated automated office diastolic blood pressure (DBP), and plasma angiotensinogen (AGT) at each scheduled visit in uncontrolled hypertensive participants on ≥ 3 antihypertensive medications.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IONIS-AGT-LRx
Study Locations (20)
California
- Advanced Research Center - Anaheim
- National Research Institute - Huntington Park - Huntington Park
- RESPIRE Research - La Mesa
- Clinical Trials Research - Lincoln
- Catalina Research Institute - Montclair
- San Fernando Valley Health Institute - Van Nuys
Florida
- ALL Medical Research, LLC - Cooper City
- Nature Coast Clinical Research - Crystal River - Crystal River
- East Coast Institute for Research - Jacksonville
- Canvas Clinical Research - Lake Worth
- Allied Biomedical Research Institute, Inc. - Miami
- AMPM Research Clinic - Miami Gardens
Alabama
- Pinnacle Research Group - Anniston
- Central Research Associates, Inc. - Birmingham
- Achieve Clinical Research, LLC - Birmingham
- Cahaba Research, Inc. - Pelham
- Syed Research Consultants LLC - Sheffield
Arkansas
- Cardiology and Medicine Clinic - Little Rock
Colorado
- Creekside Endocrine Associates, PC - Denver
Connecticut
- Chase Medical Research LLC - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2022-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04714320
The ClinicalTrials.gov registry entry for NCT04714320 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (95% lower). The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04714320 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT04714320 about?
NCT04714320 is a clinical study titled "A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure". The purpose of this study was to evaluate the effect of IONIS-AGT-LRx compared to placebo on seated automated office systolic blood pressure (SBP) from baseline to Study Day 85 in uncontrolled hypertensive participants on ≥ 3 antihypertensive medications and to evaluate the effect of IONIS-AGT-LRx o...
What is the current status of trial NCT04714320?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2021-04-28. Estimated completion is 2022-10-03.
What conditions does trial NCT04714320 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT04714320?
The interventions under investigation include: Placebo (DRUG), IONIS-AGT-LRx (DRUG).
Who is sponsoring clinical trial NCT04714320?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04714320 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.